Summary (tl;dr)

Multiple manufacturers, prominently Major Pharmaceuticals, have issued nationwide recalls for various lots of levothyroxine sodium tablets in 2026 due to concerns about the medication being "subpotent," meaning it contains less active ingredient than labeled, which could render it less effective.

Essential Background

Levothyroxine is a critical synthetic thyroid hormone prescribed daily to millions of patients to treat hypothyroidism, a condition where the thyroid gland doesn't produce enough hormones. It is also used for other thyroid-related conditions like thyroid cancer and Hashimoto's disease. Consistent and accurate dosing is vital for managing these conditions, as even small variations in potency can significantly impact a patient's health.

The Full Story

In 2026, a series of recalls for levothyroxine sodium tablets have been initiated by various pharmaceutical companies. Most recently, Major Pharmaceuticals issued a nationwide Class II recall on July 13, 2026, for specific strengths and lot numbers of its levothyroxine sodium tablets. This recall was prompted by routine stability testing which revealed that the tablets were subpotent, meaning they contain less active thyroid hormone than the amount stated on the label. The affected products include various dosages ranging from 25 mcg to 150 mcg and were distributed across the United States.

Prior to this, Macleods Pharma USA, Inc. also initiated a nationwide Class II recall on February 26, 2026, for certain 150 mcg levothyroxine sodium tablets due to similar subpotency concerns. Additionally, Lupin Pharmaceuticals, Inc. initiated a Class II recall in December 2024 (with an expiration date of July 2026 for the affected lot) for 75 mcg tablets due to failed impurity and degradation specifications.

Why It Matters

The recalls of levothyroxine are significant because patients depend on this medication for precise hormone replacement to maintain their health. If the medication is subpotent, patients may not receive the intended dose of thyroid hormone, potentially leading to the return or worsening of hypothyroidism symptoms such as fatigue, weight gain, increased sensitivity to cold, and cognitive difficulties. For vulnerable populations, including infants, pregnant women, and individuals with thyroid cancer, an inconsistent dosage can have severe implications for brain development and overall health. These recalls also erode patient trust in the safety and efficacy of their essential medications.

Geographic Location

• Indianapolis, Marion County, Indiana, United States (Major Pharmaceuticals' packaging and distribution of recalled levothyroxine tablets)
• Dublin, Franklin County, Ohio, United States (Major Pharmaceuticals, issued recall)
• Princeton, Mercer County, New Jersey, United States (Macleods Pharma USA, Inc., initiated recall)
• Baltimore, Independent City, Maryland, United States (Lupin Pharmaceuticals, Inc. headquarters, initiated recall)
• Ohio, United States (State where Lupin Pharmaceuticals' recalled products were distributed)
• United States (Nationwide distribution of recalled levothyroxine tablets)